- Exhibit & Support
- Hotel & Travel
Good news: New and emerging insulin agents—including insulin glargine U-300, regular insulin U-500, and insulin degludec U-100 and U-200—expand therapeutic options, can increase medication adherence, reduce injection burden, and facilitate normal physiological function. The downside: The increasing number of products available complicates treatment decisions for patients, prescribers, pharmacists, and other health care professionals. In this case-based workshop, pharmacists will learn about the safe and effective use of new insulin products, including strategies to titrate insulin doses, safely switch insulin products, ensure care coordination, and provide practical advice to minimize hypoglycemia.
At the completion of this application-based activity, participants will be able to: